Background: Contemporary research indicates that the legal classifications of cannabis (Schedule 2, Class B), 3,4-methylenedioxymethamphetamine (MDMA) (Schedule 1, Class A) and psilocybin (Schedule 1, Class A) in the United Kingdom are not entirely based on considerations of harm and therapeutic utility. The legal classifications of the substances discussed are typically determined by legislators such as Parliament and, therefore, may be a reflection of the views or perceived views of the general public. Objective: The aim of the study was to provide an indication of the underlying psychology regarding the legislated sale of alcohol, tobacco, cannabis, MDMA and psilocybin in pharmacies according to a UK general population sample. Methods: A sample of 105 UK nationals was selected for the survey. Participants were asked questions on perceived relative harm of the five substances. After viewing contemporary information on reported relative harm and therapeutic applications, the participants were asked questions related to using the pharmacy retail model for the sale of the substances discussed. Participants who opposed the substances being sold primarily in pharmacies were asked to explain their rationale according to a predetermined list of options for each of the five drugs. Participants were also asked whether they consider it a human right to be legally permitted to consume the substances. Results: The participants' perceptions of relative harm (tobacco > MDMA > psilocybin > alcohol > cannabis) were not in agreement with the relative harm reported in the literature (alcohol > tobacco > cannabis > MDMA > psilocybin). Principal objections to the currently illicit substances being legally available in pharmacies include it sending the wrong message; it feels wrong; it is too dangerous; disliking the smell of cannabis; disapproval of the people; and not liking the idea of people using psychoactive drugs for entertainment or to have mystical/religious experiences. Overall, the participants determined that being legally permitted to consume the substances discussed is an issue of relevance to human rights. A majority of the male participants concluded that being legally permitted to consume alcohol, tobacco, cannabis and Psilocybe mushrooms is a human right in contrast to the majority of female participants who solely considered alcohol consumption to be a human right. Conclusions: The data suggest that the legal classifications may not simply be based on considerations of harm. Misperceptions of the dangers, biases and non-health-related aversions likely contribute to the continuation of policies that do not reflect the state of scientific research.
Introduction
In a recent study by James et al. (2018) , a United Kingdom (UK) general population sample of 105 participants determined that pharmacies with available National Health Service (NHS) support from general practitioners (GPs) and mental health workers are more suitable primary vendors of cannabis, 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin than regulated shops or the black market. Participants concluded this after viewing information regarding relative harm and potential therapeutic applications of the substances (see online supplementary material). The participants considered regulated shops as more suitable primary vendors of alcohol and tobacco than pharmacies. The university-educated participants were found to be more in favour of the substances being available in pharmacies than the non-universityeducated participants. In this article, previously unpublished results obtained from the study (James et al., 2018) are reported which more carefully assess the perceptions and psychology of the participants.
Pharmacies in the UK sell devices and treatments to assist in quitting smoking, however, they do not sell substances of abuse such as cigarettes (Wyn III et al., 2012) . While some pharmacies provide harm reduction services such as needle exchange programmes for people who inject drugs (Matheson et al., 2007) , harm reduction services including the sale of the substances discussed would be a relatively new provision of the pharmacy profession (Cerda and Kilmer, 2017) . This study aims to indicate how the general public may perceive the enactment of policies designed to reduce recreational drug harms by pharmacies, perhaps counter-intuitively, selling specific drugs and providing advice on safe patterns of consumption.
The legal classifications of cannabis, MDMA and psilocybin, outlined in the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001, are arguably outdated in light of contemporary scientific research (Brewster, 2018; Nutt, 2014) . Overestimations by the general population of the harm that the substances discussed pose to the health of the consumer and societal wellbeing may help to perpetuate drug laws which, for example, state that psychedelics such as psilocybin have a high abuse potential (Canal and Murnane, 2017; Elsey, 2017; Sessa, 2015; Thiessen et al., 2018; Walsh et al., 2016) . In the study by James et al. (2018) , questions were asked to participants to assess how closely their perception of the risks associated with the use of specific (recreational) psychoactive drugs corresponds to the reported dangers posed by the substances. It was found that the participants' initial perceptions of relative harm are not in agreement with the relative harm reported in the literature (van Amsterdam et al., 2015) . These differences in perception are covered in greater detail in this article.
The participants in the study (James et al., 2018) were presented a graph, viewable in the online supplementary material, demonstrating reported relative harm of different substances of abuse including alcohol, tobacco, cannabis, ecstasy (MDMA) and mushrooms (psilocybin) . In light of their findings, Nutt et al. (2010) suggested that 'the present UK drug classification system is not simply based on considerations of harm'. An aim of this study was to determine what some of the other considerations may be. Therefore, questions were asked to provide possible explanations as to why members of the public may oppose the legislated sale of currently prohibited substances despite reported relative safety compared to alcohol and tobacco.
Aspects of the United Nations (UN) Declaration of Human Rights such as 'freedom from fear' and Articles 2 and 3, which cover 'freedom of opinion' and 'liberty', in addition to Article 14 of the European Convention on Human Rights (ECHR), which covers 'freedom from discrimination', could be relevant to use of the substances discussed (ECHR, 2010; UN, 1948) . While there are exceptions such as the Portuguese legal system which treats drug use as a health issue (Cabral, 2017) , international laws typically criminalise the use of psychoactive drugs. However, the widespread punitive approach, popularly termed the War on Drugs, has not escaped criticism (Heinze and Armas-Castan˜eda, 2015; van Ree, 1998) . The deeply contrasting perceptions of drug use and its relevance to law, individual liberty and human rights merit further investigation (Barrett, 2010; Gilmore, 1996; Scholten, 2018; Tinasti et al., 2017) .
Incarcerations and punitive measures can have lasting negative knock-on effects that in many cases are more harmful than the use of drugs (Lamb et al., 2016; Nadelmann, 1989) . Research suggests parental incarceration increases the likelihood of their children abusing drugs (Roettger et al., 2010) . Due to the harm that legal procedures can cause to personal and familial wellbeing, it was hypothesised that the use of psychoactive substances, some of which have reported potential beneficial applications (Amar, 2006; Carhart-Harris and Nutt, 2010) , may be an issue of relevance to human rights according to the UK general population.
Entheogens (Ancient Greek: entheos (e G mheoy) -'full of god' and genesthai (gem" rhai) -'to come into being' or 'generate') are naturally occurring hallucinogenic compounds that can induce 'mystical' or 'mysticaltype' experiences (Blinderman, 2016; Griffiths et al., 2006 Griffiths et al., , 2008 . Whilst arguably only relevant to a minority of the UK general population, Article 18 of the UN Universal Declaration of Human Rights (UN, 1948) and Article 9 of the ECHR (ECHR, 2019) could be interpreted to suggest that the use of naturally occurring entheogens such as mescaline, derived from San Pedro and Peyote cacti (El-Seedi et al., 2005; Ogunbodede et al., 2010) , and psilocybin, derived from Psilocybe mushrooms, is an issue of relevance to human rights due to their uses in religious (Richards, 2005) , shamanic (Metzner, 1998) and spiritual healing practices . However, the view that using certain drugs is part of freedom of religion is not the generally accepted opinion.
Consumption of entheogens and cannabis is not considered a human right by law in the UK, although access to medicinal cannabis as a human rights issue has been discussed in legal proceedings (Bone and Seddon, 2016) . Whilst the criminalisation of individuals who claim to use cannabis to ameliorate their physiological or psychological condition raises ethical questions (Baker et al., 2003; Grotenhermen and Muller-Vahl, 2012; Stevens, 2018) , the Mexican Supreme Court has previously ruled that being legally permitted to consume cannabis is a human right (Aguinaco and Barra, 2017; Delman, 2015; Ingraham, 2015) .
The research described may be of relevance for the development of reformed drug policy in the UK. Policymakers such as Members of Parliament and Cabinet Ministers are perhaps susceptible to the same perceptions as the general population. Not only are they likely to be susceptible to the same perceptions as the general population but they may feel pressure to appease those perceived views. This study aims to provide an indication of the underlying biases of members of the general public and, ultimately, the government which may act as psychological obstacles to the successful enacting of legislative changes in drug policy.
Methods
The research described in this article was approved by the Cardiff University School of Psychology ethics committee and was carried out with the informed consent of the participants.
Participant recruitment
Participants were recruited from the Qualtrics research panel, a volunteer panel that participate in online surveys. The general aim of the study was described as: 'This study concerns the relative perceptions and psychology of risk and risk management of specific drugs'.
Survey administration
The survey was designed so that it could be completed without detailed knowledge of the topic due to the sample being a general population sample. The scientific content was minimised to reduce the likelihood of problems with compliance and understanding of the data and information provided. Participants were required to complete the survey in one sitting. The survey was administered using Qualtrics software involving an online survey and data-collection tool.
The survey was administered in three phases: (1) participants were initially asked about perceptions of relative harm of the different drugs; (2) participants were then presented with information regarding reported relative harm and potential therapeutic applications; and (3) participants were then asked questions relating to the use and sale of the substances discussed. The contents of the survey are viewable in the online supplementary material.
Inclusion criteria
All participants were required to consent to participating in the study, be UK nationals and be aged 18 years or older.
Questions
The first question relevant to this report was designed to record participants' perceptions of relative harm and was answerable on a scale of 1-5. The second question was multiple choice with six options. All the following questions used a 1-10 response scale with 1 signifying strong disagreement and 10 signifying strong agreement. For each of the questions, respondents were asked to answer the question relative to alcohol, tobacco, cannabis, MDMA and magic mushrooms/ psilocybin. The wording of the questions was kept as consistent and understandable as possible.
Demographics
Participants provided basic demographic information regarding: age, education, gender, religion and profession. Participants were also invited to include: 'other relevant personal information'.
Results

Survey completion
All 105 participants consented to taking part in the survey and completed it.
Participant characteristics
The demographics of the 105 participants can be summarised as follows: 53 males and 52 females; 20 participants aged 18-24 years, 22 aged 25-34 years, 21 aged 35-44 years, 21 aged 45-54 years and 21 aged 55 þ years; all UK nationals; 17 with General Certificate of Secondary Education (GCSEs) or equivalent, 23 with A-levels or equivalent, 5 with vocational training (e.g. apprenticeship), 47 with a bachelor's degree, 9 with a master's degree and 4 with a PhD; and 24 atheists, 8 agnostics, 43 Christians, 2 Muslims, 1 Hindu, 1 other and 26 no religion.
Perceived harm
Question: 'Please give each of the five substances listed a number between 1-5 where (1) is not at all harmful to the consumer and to others and (5) is very harmful based on your understanding and experience. Please take addictive potential, typical regularity of consumption and long-term effects over an individual's lifetime into account' (Table 1) . Table 1 shows the mean perceived harm ratings and the perceived relative harm was in the following order:
Tobacco 4 MDMA 4 psilocybin 4 alcohol 4 cannabis An analysis of variance showed a significant effect of drug type (F4,416 ¼ 28.9, p < 0.001). The perceived relative harm was different from the relative harm reported in the literature van Amsterdam et al., 2015) :
Alcohol 4 tobacco 4 cannabis 4 MDMA 4 psilocybin Question: 'How many deaths due to the following psychoactive substances per 100,000 consumers do you think happen each year in the UK?' (Tables 2 and 3) .
The participants had six multiple choice options to answer this question, and the available choices were: 0-1, 1-10, 10-100, 100-400, 400-800 and 800-1200. The frequency of responses for each option are presented in Table 2 . The calculated number of deaths per 100,000 consumers per year for each of the five substances was determined from available materials (ASH, 2015; BBC Science and Nature website; Ghodse et al., 2012; HSCIC, 2015; Lader, 2015;  Office for National Statistics, 2011; Office for National Statistics: Alcohol-related deaths in the UK) and can be viewed in Tables 2 and 3. A Friedman two-way analysis of variance by ranks showed significant differences between the drugs (p < 0.001). The participants most accurately determined the deaths per 100,000 consumers for tobacco; however, around 50% of the participants underestimated tobacco fatalities. Although a minority of the sample did accurately determine the deaths per 100,000 consumers of alcohol, cannabis, ecstasy and Psilocybe mushrooms, the participants generally overestimated the deaths per 100,000 consumers. More than 75% of the participants overestimated alcohol-related deaths, more than 85% of the participants overestimated cannabis deaths, more than 89% of the participants overestimated the number of deaths due to ecstasy and more than 90% of the participants overestimated the number of deaths due to Psilocybe mushrooms.
Aversions to the substances in pharmacies
Participants who selected 4 or under out of 10 for the substances being available in pharmacies (James et al., 2018) , suggesting opposition to the proposed change in policy, were invited to explain their rationale according to a predetermined list of options. Participants who selected 5 (or above) were not required to give an explanation for their opposition as '5' is arguably the number most analogous to a 'neither agree nor disagree' response on a 1-10 scale and a selection of 6 or above would suggest agreement with the proposed change. Figures 1 to 3 show the mean ratings for the different proposed aversions for cannabis, MDMA and psilocybin, respectively. The aversions to alcohol and tobacco being primarily available in pharmacies which had a mean rating of 6 or above out of 10, suggesting overall agreement with the aversion, were: it simply is not practical or realistic, restricting alcohol sales to pharmacies would harm many people's livelihoods, some tobacco addicts would find it hard to adapt to the changes and that as alcohol and tobacco have no reported or potential therapeutic applications, they do not belong in pharmacies. The data for these questions can be found in the online supplementary material.
Question: 'If cannabis were to be legalised for medicinal and recreational use and sold in pharmacies with available NHS support from GPs and mental health workers, as 1. A safer recreational drug alternative to alcohol and tobacco 2. compounds (such as THC, CBD and other cannabinoids) and 3. So pharmacists can give advice and guidance on safe usage practices, this would be a positive change that you would support'. Data for this question have been previously reported (James et al., 2018) , and here it is reported that 18 of 105 participants selected 4 or under, suggesting opposition to the proposed change in policy with regard to cannabis being available in pharmacies, and explained their rationale according to a predetermined list of options. Three of the available options had an overall mean score of 6 or above and these were: 'it feels wrong', 'it sends the wrong message to people' and 'you do not like the smell of cannabis' (Figure 1) .
Question: 'If MDMA were to be legalised for therapeutic and recreational use and sold in pharmacies with available NHS support from GPs and mental health workers, as 1. A safer recreational drug alternative to alcohol and tobacco 2. A rational evidence-based solution to the ongoing problem of unregulated party drugs such as mephedrone 3. A potential therapeutic tool for psychotherapy and 4. So pharmacists can give advice and guidance on safe usage practices, this would be a positive change that you would support.'
Data for this question have been previously reported (James et al., 2018) , and here it is reported that 30 of 105 participants selected 4 or under, suggesting opposition to the proposed change in policy with regard to MDMA being available in pharmacies, and explained their rationale according to a predetermined list of options. Five of the options had a mean score of 6 or above and these were: 'it is too dangerous', 'it feels wrong', 'it sends the wrong message to people', 'you cannot accept or approve of people who take MDMA' and 'you do not like the idea of people using psychoactive drugs for entertainment' (Figure 2) . Question: 'If magic mushrooms were to be legalised for therapeutic and recreational use and sold in pharmacies with available NHS support from GPs and mental health workers, as 1. A safer recreational drug alternative to alcohol and tobacco 2. A potential therapeutic tool for psychotherapy and 3. So pharmacists can give advice and guidance on safe usage practices, this would be a positive change that you would support.'
Data for this question have been previously reported (James et al., 2018) , and here it is reported that 28 of 105 participants selected 4 or under, suggesting opposition to the proposed change in policy with regard to psilocybin being available in pharmacies, and explained their rationale according to a predetermined list of options. Three of the options had a mean score of 6 or above and these were: 'it feels wrong', 'it sends the wrong message to people' and 'you do not like the idea of people using psychoactive drugs to have mystical/ religious experiences' (Figure 3 ).
Human rights
Question: 'Being legally permitted to consume the five substances discussed is a human right' (Figure 4 ; Tables 4 and 5) .
Statistical analysis showed a high level of statistical significance for drug effect (F 4,416 ¼ 22.1, p < 0.001). A multivariate analysis on the whole sample of 105 participants revealed no statistically significant difference in scores for education, religion or age. Females generally had lower scores, and the gender difference was greater for cannabis, MDMA and psilocybin compared to alcohol and tobacco (Figure 4 ; Tables 4 and 5).
Discussion
The perceptions of the UK general population sample used in this study regarding the relative harm of alcohol, tobacco, cannabis, MDMA and psilocybin were not in agreement with the relative harm reported in the literature van Amsterdam et al., 2010 van Amsterdam et al., , 2015 . No significant differences were observed between the university-educated and nonuniversity-educated groups regarding the perceived harm. The participants underrated alcohol harm relative to Psilocybe mushrooms, MDMA and tobacco (Table 1) . Interestingly, however, when asked to determine deaths per 100,000 consumers, the participants overrated alcohol harm although not as significantly as for cannabis, MDMA and psilocybin (Tables 2 and  3 ). The participants' perceived harm of the substances matched more closely with the harm according to the legal classifications than the reported relative harm. These differences in perception likely reflect the differences in legal reality (Class A, Schedule I for psilocybin) and objective harm (0-1 deaths per 100,000 consumers reported for psilocybin) ( Table 3) .
The participants with an aversion to alcohol and tobacco being sold primarily in pharmacies cited reasons that were not unexpected (see online supplementary material). Alcohol is widely available in many types of retail outlet and is sold principally as a drink as opposed to a drug. Alcoholic drinks only being sold in pharmacies would lead to the closure of pubs and other venues which would likely cause loss of livelihood to many people involved in the alcoholic drinks industry. Due to the current availability of alcohol and tobacco in other forms of outlet, making pharmacies the primary providers of the substances would require a fundamental overhaul of a major sector of the economy and practically would be difficult to achieve. Understandably, many participants questioned the utility of such a dramatic change as alcohol and tobacco have no reported therapeutic applications.
'It sends the wrong message to people' was a significant aversion for the participants who opposed the currently illicit substances being available in pharmacies. The question, therefore, could be how can an informed and balanced message be established amongst the general public? Although the prohibition of highly addictive, historically freely available drugs, such as heroin, originally led to a decrease in usage (DuPont and Voth, 1995; Handley et al., 2017) , prohibition has not stopped people using cannabis in high numbers (Hickman et al., 2007; Werb et al., 2013) . Despite possession of MDMA carrying a sentence of up to seven years in prison in the UK, criminalisation does not dissuade millions of young people worldwide from using it (UNODC, 2017) . The Home Office (2018) has estimated that around a fifth of 16-24 year olds in England and Wales use illicit drugs annually. Consequently, it could be argued that current legal classifications are an ineffective deterrent for use.
Currently, most cannabis users in the UK buy cannabis from unregulated black market vendors. Unlike pharmacists (Dessing, 2000) , 'drug dealers' do not need to follow an ethical code of conduct (Fast et al., 2017; Klein and Potter, 2018) and have no obligation to encourage moderated usage or to sell strains more suitable for therapeutic applications (Bhattacharyya et al., 2018; Sartim et al., 2018; Schubart et al., 2011; Wall et al., 2019) . Most black market vendors in the UK cannot offer a broad variety of strains and do not have medical training or knowledge of what they are selling and how it could positively and negatively impact the health of the consumer (Hurley, 2018) . The vendors of cannabis in illicit markets are arguably not the individuals most suited to delivering healthfocused advice, especially as their livelihood is dependent on continued sales which can discourage them from acting in their customers' interests (Reddon et al., 2019) .
A variety of community members typically take a role in sending a message regarding drug use, including teachers, parents, police officers and medical healthcare professionals. As drug laws should seek to reduce harm to individual wellbeing and support potential medical uses, arguably medical healthcare professionals are the professional group most suited to sending an informed and balanced message that consumers and the general public can believe . Previous data (James et al., 2018) have suggested that the UK general population would favour cannabis being accessible in pharmacies with available support from GPs and mental health workers. An initial consultation with a GP or specialist could facilitate initial contact between the consumer and healthcare professionals and enable the consumer to feel comfortable discussing their substance use in a medical context. After an initial consultation, pharmacists would be able to take an active role in educating and advising consumers on safe usage practices. In this model, the professionals most suited to giving factual advice regarding the use of drugs -doctors and pharmacists -can effectively send a message consistent with contemporary scientific understanding. 'It feels wrong' was a contributing factor for participants with an aversion to cannabis being available in pharmacies. International condemnation of marijuana and its users by governments may have been an influence that led to 'it feels wrong' being a significant aversion towards cannabis being available in pharmacies (Stringer and Maggard, 2016) . Other persistent implicit beliefs suggesting cannabis users are dangerous may also have been influential (Daftary, 1990) .
Disliking the smell of cannabis was the second most significant aversion towards cannabis being available in pharmacies. Whilst disliking the smell of cannabis is a dubious basis for maintaining the legal status quo, in light of these data, future regulation should at least take this factor into consideration. Concerns surrounding the health effects of second-hand smoke may also have contributed to the prominence of this result. Restricting public cannabis use to outdoor smoking areas would minimise public exposure to second-hand smoke and bring public use in line with existing smoking legislation. Vaporising does not produce such intense aromas and is reportedly less harmful than smoking and, consequently, recommending this route of administration would be consistent with the overall objectives of harm reduction (Loflin and Earleywine, 2015; Russell et al., 2018) .
As suggested by the perceived harm data, the participants considered high purity pharmaceutical quality MDMA to be comparatively dangerous (Table 1) . This is corroborated in the data obtained for the aversions (Figure 2) . The participants may have been confusing illicit black market MDMA of highly variable quality (Couchman et al., 2019) with high quality MDMA dispensed in a healthcare setting. MDMA produced to good manufacturing practice standards is reportedly well tolerated when used at recommended doses (Mithoefer et al., 2018; Sessa et al., 2019) . The general perception that MDMA is more dangerous than suggested by previous research (van Amsterdam et al., 2015) may be due to the legal classification of MDMA (Class A) and biased media coverage (Measham, 2004) . MDMA has received generally disproportionate negative media attention with a particular emphasis on harm (Hurley, 2017; McAndless, 2009) . In contrast, alcohol, which is the leading cause of death in men between the ages of 16 and 54 years, does not receive proportionate coverage in the media regarding the significant dangers posed by alcohol consumption (Nutt and Rehm, 2014) . The bias towards the reporting of unusual events is likely to contribute to the disagreement between the general public's perceptions of the dangers posed by the substances and contemporary scientific research. Negative media coverage, its prevalence in the rave scene and the legal classifications may also have influenced participants to think that MDMA being available in pharmacies 'feels wrong' (Figure 2) .
The result of 'you cannot accept or approve of people who take MDMA' having a mean rating over 6 out of 10 is perhaps evidence of conformity to accepted legal reality. While the demographics of MDMA users are varied and span a range of socioeconomic groups (Wu et al., 2009) , the disapproval of the consumers may be based on generalised stereotypes. It could be due to the fact that MDMA is illegal that some of the participants did not approve of the users and were opposed to envisioning a reality in which MDMA consumption were legal.
The most significant aversion to the proposed change in policy regarding MDMA, greater than concerns about the dangers, was that some participants did not like the idea of people using psychoactive drugs for entertainment ( Figure 2 ). However, when looking at data for individuals in the survey, it has been found that of the 23 people who chose this as an aversion to MDMA being available in pharmacies, 17 of them (74%) determined that alcohol consumption is a human right. This is consistent with a general belief in a false dichotomy that alcohol and tobacco are not drugs in the sense that illicit drugs are (Gilmore, 1996) . Perhaps the word 'psychoactive' has a negative connotation in the minds of some participants who may not be aware that alcohol is a psychoactive drug (Measham, 2004; Szmigin et al., 2008) .
As with the other currently illicit substances, 'It feels wrong' was a significant aversion towards psilocybin being available in pharmacies (Figure 3 ). Such perceptions are likely based on the proposed similar rationale to the other substances that it is already illegal, and participants struggle to envision a reality in which psilocybin is socially acceptable. In other cultures where psychedelic drugs are used in ritual healing ceremonies (Carod-Artal, 2015) , it is unlikely many participants would have a bad feeling at the suggestion of a healing substance being available in a pharmacy.
Curiously, despite a lack of general religious objection (Figure 3) , the second most significant aversion towards psilocybin being available in pharmacies was that certain participants did not like the idea of people using psychoactive drugs to have mystical/religious experiences. There are perhaps two points of note with regard to this finding. First, it arguably contravenes the aforementioned human rights declarations concerning freedom for spiritual and religious practice (Doblin, 1991; ECHR, 2019; UN, 1948) . Second, some of the therapeutic benefits of psilocybin use have been highly correlated with types of experiences defined as being mystical or mystical-type (Griffiths et al., 2006 MacLean et al., 2011) . It is possible that the participants were not aware that the mystical-type experience is a scientifically accepted phenomenon (Griffiths et al., 2016; Johnson et al., 2019) . Therefore, the data (Figure 3 ) suggest that the public may need to be educated on the potential benefits (Garcia-Romeu et al., 2014) of such experiences and that they can be attained by both religious and non-religious individuals (Yaden et al., 2017) . Due to the importance of set and setting in psilocybin-assisted psychotherapy, it is also likely that a widespread societal aversion to psilocybin occasioned mystical-type experiences could hinder the therapeutic viability of the treatment (Carhart-Harris et al., 2018; Hartogsohn, 2016 Hartogsohn, , 2017 . Public resistance could be challenging for future applications of psilocybin which, research suggests, have implications for improved mental (Carhart-Harris et al., 2016) , physical (Bogenschutz et al., 2015) and societal wellbeing (Hendricks et al., 2018; James et al., 2019; Nour et al., 2017; Walsh et al., 2016) .
An original purpose of the study was to determine if there may be any demographic trends such as age, educational level and religion amongst participants with regard to the aversions towards the substances being available in pharmacies. For example, it has been hypothesised that some individuals of a Judeo-Christian background may have a pre-defined or preconceived aversion to psychedelic use due to persisting implicit beliefs without explicit connection to historical events (Santiago et al., 2016) ; and that some participants who identify as non-religious or atheist may object to mystical experiences on the grounds of an overall aversion or suspicion of religion and spirituality. However, due to the size of the sample in this study, e.g. 28 participants averse to regulation of psilocybin, it is not possible to draw any statistical conclusions regarding the demographics of the participants and their aversions towards the substances discussed being available in a healthcare setting. Further research into the demographic trends and rationale underlying aversions towards regulation of specific psychoactive substances is warranted. Greater understanding of the psychological obstacles to evidence-based policies could lead to improvements in the health of the population.
The statistically significant difference between males and females, when asked whether the consumption of the substances discussed is a human right, was an unexpected result (Table 5 ). This was especially surprising considering that there was no significant difference between males and females with regard to support for regulation as this was split more across educational background (James et al., 2018) . It has previously been found that females have tended to be less likely to support legalisation of marijuana (Palamar, 2014) . It is also documented that criminality, drug use, risktaking and novelty-seeking behaviours are more common in men (Cropley, 2013; Pawlowski et al., 2008; Satoshi, 2003; Tamas et al., 2019) . As women may be less inclined to deviate from the current legal framework, this could help to explain why the gender difference in perceived human rights was observed (Hine, 2019) . Perhaps the observed difference in perception between males and females with regard to human rights and use of the substances discussed can be most adequately explained in terms of evolutionary psychology (Buss, 2009; Diep, 2015) . The evolutionary, psychobiological and socio-environmental bases for these differences in perception merit further investigation.
While the human rights results (Figure 4 ; Tables 4 and 5) demonstrate significant disagreement within the sample, the results are indicative of cultural bias. The population sample used were all UK nationals, and alcohol's rating as being more of a human right than any of the other substances is perhaps attributable the participants' culture. Alcohol is ubiquitous in British and Irish societies and the legal classifications, historical usage and contemporary cultural prevalence of the substances likely contribute to the trends observed. It would be interesting to ask the human rights question to a different population sample, as it is possible that in cultures where psychedelics are used in religious and healing ceremonies that psilocybin would be rated more highly as a human right. Native inhabitants of Mexico traditionally used mescaline (Carod-Artal, 2015), a psychedelic similar to psilocybin in its effects, but they reportedly disapproved of alcohol. In the United States, in some circumstances and locations, the use of mescaline is legal for use in religious ceremonies and is legally permissible for members of the Native American Church (Jones, 2007) . Most Muslim cultures forbid alcohol; however, certain Islamic cultures have permitted the use of cannabis and opium (Gilmore, 1996) .
Cannabinoids are highly lipophilic and can remain detectable in the human body for months (Huestis, 2007) . Drug testing for cannabis does not reliably indicate intoxication due to the lipophilicity of the molecules and consequently drug testing in the work environment is not useful and is perhaps discriminatory. Mandatory drug testing to detect cannabinoids in sports people is problematic as cannabis is not reportedly performance enhancing (Saugy et al., 2006) . These real-world outcomes of cannabis prohibition may have contributed to the result that the male and universityeducated subgroups determined that consumption of cannabis is an issue of relevance to human rights ( Table 5 ). The endocannabinoid system may also have been a contributory factor for these results (Fine and Rosenfield, 2013; McPartland et al., 2006) .
A majority of the sample did not perceive the consumption of MDMA to be of relevance to human rights, and it was only the male university-educated subgroup that determined being legally permitted to consume high-quality MDMA is a human right ( Table 5 ). The lower human rights results for MDMA may be due to the fact that MDMA is synthetic, unlike tobacco, cannabis and Psilocybe mushrooms, and therefore not of natural product origin. Lack of historical usage of MDMA may have contributed to the results as psilocybin, tobacco, alcohol and cannabis have been used for, at least, millennia (Carhart-Harris et al., 2016; Crocq, 2007) .
It has been posited that research suggests an evolutionary divergence between Homo sapiens and other hominids in their capacity to ingest and use plant and fungal toxins including psilocybin (Winkelmann, 2017) . Research has demonstrated that negative psychological events can mediate epigenetic effects (Carey, 2012; Elliott et al., 2010; Uchida et al., 2011; Weaver et al., 2004) . Positive psilocybin experiences may have the potential to affect epigenetic changes that could have implications for human development (Martin and Nichols, 2017) . Perhaps there is an argument for the consumption of specific compounds to be an issue of relevance to rights and personal freedoms if there is the potential to positively impact human evolution (Tafur, 2017) .
To conclude, while the data obtained for the proposed aversions provide an indication of some underlying perceptions of members of the UK general population, the sample size limits applicability to the general population as a whole and no hypotheses as to the demographic trends or statistical significance of the results can be derived from the data (Figures 1, 2 and  3) . The drug taking histories of the participants are unknown and, although the sample covers a range of demographics, the sample used cannot realistically be considered as being representative of the UK general population as, for example, over 55% of the sample had a university qualification (HESA, 2018) . The general population may be more averse to regulation of the substances discussed and have more extreme misperceptions than suggested by the data as some of the participants may have been conscious of the purpose of the study and tempered their responses as a result. In addition, the specific wording of the questions may be important in determining certain responses and there may be alternative explanations for the perceptions of participants which were not explored in this paper and further research on this issue is required. Furthermore, it should be noted that, due to the observer-expectancy effect, the views and biases of the investigators conducting this study may have influenced the results and the interpretation of them (Klein et al., 2012) . Therefore, perhaps this study could equally be considered a sociological record of the perceptions of early 21st century researchers as it is of the perceptions of 105 UK general population participants.
In summary, the data obtained in this study could be used by legislators to inform decision-making processes regarding regulation of the substances discussed. The data suggest that the legal classifications of cannabis, MDMA and psilocybin are likely not only due to considerations of harm. The participants determined that consumption of the substances discussed is a human rights issue. A majority of the female participants solely perceived alcohol consumption to be a human right in contrast to a majority of the male participants who concluded that being legally permitted to consume alcohol, tobacco, cannabis and Psilocybe mushrooms is a human right. Considerations for the legal classifications of the substances discussed as suggested by the data include misperceptions of the dangers, not liking the smell of cannabis, disapproval of the people who use the substances and not liking the idea of people using psychoactive drugs for entertainment or to have mystical/religious experiences.
